Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series

被引：2
|
作者：
Bernstein, Ezra [1 ]
Luo, Jia [2 ]
Wang, Kaiwen [3 ]
Negrao, Marcelo V. [4 ]
Janne, Pasi A. [2 ]
Sabari, Joshua K. [5 ]
机构：
[1] NYU, Langone Dept Internal Med, 251 East 33rd St, New York, NY 10016 USA
[2] Dana Faber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX USA
[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
来源：
JCO PRECISION ONCOLOGY | 2024年 / 8卷
关键词：
D O I：
10.1200/PO.23.00447
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Case series demonstrates activity of adagrasib in untreated CNS metastases across multiple scenarios.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.
    Mok, Tony S. K.
    Lawler, William E.
    Shum, Merrill Kingman
    Dakhil, Shaker R.
    Spira, Alexander I.
    Barlesi, Fabrice
    Reck, Martin
    Garassino, Marina Chiara
    Spigel, David R.
    Alvarez, Delia
    Kheoh, Thian
    Paxton, William
    Chao, Richard C.
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
    Sabari, Joshua K.
    Velcheti, Vamsidhar
    Shimizu, Kazuhide
    Strickland, Matthew R.
    Heist, Rebecca S.
    Singh, Mohini
    Nayyar, Naema
    Giobbie-Hurder, Anita
    Digumarthy, Subba R.
    Gainor, Justin F.
    Rajan, Anant P.
    Nieblas-Bedolla, Edwin
    Burns, Aaron C.
    Hallin, Jill
    Olson, Peter
    Christensen, James G.
    Kurz, Sylvia C.
    Brastianos, Priscilla K.
    Wakimoto, Hiroaki
    CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3318 - 3328
  • [33] Exploratory biomarker analyses from a phase 2 trial evaluating sotorasib in patients with pre-treated KRASG12C-mutated non-small cell lung cancer (CodeBreaK 100)
    Schuler, M.
    Italiano, A.
    Li, B.
    Dy, G.
    Skoulidis, F.
    Kato, T.
    Anderson, A.
    Ang, A.
    Ngarmchamnanrith, G.
    Addeo, A.
    Wolf, J.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S38 - S38
  • [34] KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
    Mok, Tony S. K.
    Yao, Wenxiu
    Duruisseaux, Michael
    Doucet, Ludovic
    Azkarate Martinez, Aitor
    Gregorc, Vanesa
    Juan-Vidal, Oscar
    Lu, Shun
    De Bondt, Charlotte
    de Marinis, Filippo
    Linardou, Helena
    Kim, Young-Chul
    Jotte, Robert M.
    Felip, Enriqueta
    Lo Russo, Giuseppe
    Reck, Martin
    Michenzie, Mary F.
    Yang, Wenjing
    Meade, Julie N.
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8509 - LBA8509
  • [35] A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
    El Saadany, Tamer
    Lupatsch, Judith E.
    Mark, Michael
    Barbier, Michaela
    Mehra, Tarun
    Schwenkglenks, Matthias
    von Moos, Roger
    SWISS MEDICAL WEEKLY, 2025, 155
  • [36] The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients
    Liu, Yan
    Li, Hui
    Zhu, Jing
    Zhang, Yang
    Liu, Xianhong
    Li, Rixin
    Zhang, Qiang
    Cheng, Ying
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2447 - 2454
  • [37] Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.
    Goldberg, Sarah B.
    Gettinger, Scott N.
    Mahajan, Amit
    Herbst, Roy S.
    Chiang, Anne C.
    Tsiouris, A. John
    Vortmeyer, Alexander
    Jilaveanu, Lucia
    Speaker, Stephanie
    Madura, Matthew
    Rowen, Elin
    Gerrish, Heather
    Knapp-Perry, Elizabeth
    Yao, Xiaopan
    Chiang, Veronica
    Kluger, Harriet M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients
    Swart, E.
    Noordhof, A. L.
    Damhuis, R. A. M.
    Kunst, P. W. A.
    De Ruysscher, D. K. M.
    Hendriks, L. E. L.
    van Geffen, W. H.
    Aarts, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S349 - S349
  • [39] ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN
    Fernandez-Barcelo, C.
    Abbas, I
    Botella, X.
    Aguilo Domingo, M.
    Cots, F.
    Siles Cuesta, C.
    Arriola, E.
    Gas Lopez, M. E.
    Lopez Gomez, C.
    Juan-Vidal, O.
    Planellas, L.
    Lloansi, A.
    Sanchez, J.
    Reguart, N.
    Sampietro-Colom, L.
    VALUE IN HEALTH, 2023, 26 (12) : S521 - S521
  • [40] Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
    Lu, S.
    Jian, H.
    Zhang, Y.
    Song, Z.
    Zhao, Y.
    Wang, P.
    Jiang, L.
    Gong, Y.
    Zhou, J.
    Dong, X.
    Yang, N.
    Fang, J.
    Zhuang, W.
    Cang, S.
    Ma, R.
    Shi, J.
    Wu, P.
    Lu, J.
    Xiang, Z.
    Shi, Z.
    Zhang, L.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S11 - S11
12345